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Abstract
Metabolic syndrome (MetS) is a complex disorder
defined by a cluster of interconnected factors that
increase the risk of cardiovascular atherosclerotic
diseases and diabetes mellitus type 2. Currently,
several different definitions of MetS exist, causing
substantial confusion as to whether they identify the
same individuals or represent a surrogate of risk
factors. Recently, a number of other factors besides
those traditionally used to define MetS that are also
linked to the syndrome have been identified. In this
review, we critically consider existing definitions and
evolving information, and conclude that there is still a
need to develop uniform criteria to define MetS, so as
to enable comparisons between different studies and
to better identify patients at risk. As the application of
the MetS model has not been fully validated in
children and adolescents as yet, and because of its
alarmingly increasing prevalence in this population,
we suggest that diagnosis, prevention and treatment
in this age group should better focus on established
risk factors rather than the diagnosis of MetS.
Introduction
Metabolic syndrome (MetS) is a complex disorder with
high socioeconomic cost that is considered a worldwide
epidemic. MetS is defined by a cluster of interconnected
factors that directly increase the risk of coronary heart
disease (CHD), other forms of cardiovascular athero-
sclerotic diseases (CVD), and diabetes mellitus type 2
(DMT2). Its main components are dyslipidemia (ele-
vated triglycerides and apolipoprotein B (apoB)-contain-
ing lipoproteins, and low high-density lipoproteins
(HDL)), elevation of arterial blood pressure (BP) and
dysregulated glucose homeostasis, while abdominal
obesity and/or insulin resistance (IR) have gained
increasing attention as the core manifestations of the
syndrome. Recently, other abnormalities such as chronic
proinflammatory and prothrombotic states, non-alco-
holic fatty liver disease and sleep apnea have been
added to the entity of to the syndrome, making its defi-
nition even more complex. Besides the many compo-
nents and clinical implications of MetS, there is still no
universally accepted pathogenic mechanism or clearly
defined diagnostic criteria. Furthermore, there is still
debate as to whether this entity represents a specific
syndrome or is a surrogate of combined risk factors that
put the individual at particular risk. A main evolving
aspect of MetS is its increasing prevalence in both child-
hood and young adulthood and the future implications
to the global health burden this may confer. In the pre-
sent work we discuss the importance of establishing
clear criteria to define MetS, highlighting the latest
research, which we use to provide a critical review of
currently existing controversies in this field and expand
on the childhood and adulthood aspect of the syndrome.
Currently used criteria to define MetS
Historically, Reaven was the first to put forward the
concept of ‘syndrome X’, (which he later renamed
MetS), hypothesizing that it was a central feature in the
development of CHD and DMT2, mainly through target
tissue resistance to insulin action [1]. Since then, many
international organizations and expert groups, such as
the World Health Organization (WHO), the European
Group for the study of Insulin Resistance (EGIR), the
National Cholesterol Education Program Adult Treat-
ment Panel III (NCEP:ATPIII), the American Associa-
tion of Clinical Endocrinology (AACE), the International
Diabetes Federation (IDF), and the American Heart
Association/National Heart, Lung, and Blood Institute
(AHA/NHLBI), have attempted to incorporate all the
different parameters used to define MetS (Appendix 1).
The first attempt was made in 1998 by the WHO,
which proposed that MetS may be defined by the
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any medium, provided the original work is properly cited.presence of IR or its surrogates, impaired glucose toler-
ance (IGT) or DMT2, as essential components of the
syndrome, along with at least two of the following para-
meters: raised BP, hypertriglyceridemia and/or low
HDL-cholesterol, obesity (as measured by waist/hip
ratio or body mass index (BMI)), and microalbuminuria
[2]. Shortly thereafter, the EGIR excluded microalbumi-
nuria as an integral component of the syndrome, while
it required hyperinsulinemia to be present [3]. In addi-
tion, waist circumference and not BMI was regarded as
the main indicator to assess obesity, while introducing
different cut-offs from those previously used for the
other components of the syndrome. In 2001, the NCEP:
ATPIII published a new set of criteria that included
waist circumference, blood lipids, BP, and fasting glu-
cose [4]. The NCEP:ATPIII definition differed from
both the WHO and EGIR definitions in that IR was not
considered as a necessary diagnostic component. In
2005, the International Diabetes Federation (IDF) pub-
lished newer criteria in an attempt to define the syn-
drome more precisely so that it could be used by
different clinical and research groups. The aim of this
new definition was to enable comparisons between
study results, in the hope that it would be a better pre-
dictor of risk particularly for CHD, stroke and DMT2
[5]. The IDF introduced abdominal obesity as a prere-
quisite of the diagnosis of MetS, with particular empha-
sis on waist measurement as a simple screening tool
that was also adopted by AHA/NHLBI [6].
The remaining four components of MetS were identi-
cal in the AHA/NHLBI definition to those of the IDF,
although abdominal obesity was defined differently. The
IDF recommended that the threshold for waist circum-
ference in Europeans should be 94 cm for men and 80
cm for women, while the AHA/NHLBI recommended
cut-off points of 102 and 88 cm, respectively.
Currently, the two most widely used definitions are
those of the NCEP:ATP III and IDF focusing specifically
on waist circumference, which is a surrogate measure of
central obesity. In contrast, the AACE, WHO and the
EGIR definitions are all largely focused on insulin
resistance.
However, a major problem with the WHO and NCEP:
ATPIII definitions has been their applicability to differ-
ent ethnic groups, especially when trying to define obe-
sity cut-offs. This is particularly evident for the risk of
DMT2, which is apparent at much lower levels of obe-
sity in Asians compared to Europeans. The IDF, having
recognized the difficulties in identifying unified criteria
for MetS that were applicable across all ethnicities, has
proposed a new set of criteria with ethnic/racial specific
cut-offs [7]. However, even in Westerners, a difference
of 14 cm in current abdominal obesity criteria across
genders may be debatable, leading to dilution of MetS
in women or a failure of encompassing men with MetS
at increased cardiometabolic risk.
In view of these difficulties and until more evidence
that can elucidate the cause of MetS accumulate, the
Joint Interim Statement (consensus definition in Appen-
dix 1) highlighting that there should be no obligatory
component for MetS but rather all individual compo-
nents should be considered important on risk predic-
tion, is currently mostly accepted.
Although prevalence estimates for the syndrome have
been mostly similar in any given population regardless
of the definition used, different individuals are identified
[8]. This is attributed to the different focus of each defi-
nition, from the glucocentric WHO definition to an
obesity-centric IDF one, and to a collection of statisti-
cally related CVD risk factors by the NCEP:ATPIII defi-
nition. Taking into account the burgeoning epidemic of
DMT2 and CVD worldwide, the need for one practical
definition that would identify accurately individuals with
MetS is becoming imperative.
Epidemiology of MetS according to the various
definitions used
Clearly, the prevalence of MetS varies and depends on
the criteria used in different definitions, as well as the
composition (sex, age, race and ethnicity) of the popula-
tion studied [9]. No matter which criteria are used, the
prevalence of MetS is high and rising in all western
societies, probably as a result of the obesity epidemic
[10-12]. According to National Health and Examination
Survey (NHANES) 2003-2006 [13], approximately 34%
of people studied met the NCEP:ATPIII revised criteria
for MetS. Differences in the age-adjusted prevalence
estimates using the various definitions of MetS within
three NHANES cohorts (1988-1994, 1999-2002 and
2 0 0 3 - 2 0 0 6 )a r es h o w ni nT a b l e1 .U s i n gt h er e v i s e d
NCEP:ATPIII criteria, the estimated prevalence of MetS
increased up to 5% during the last 15 years. The WHO
criteria, although more restrictive, estimated nearly the
same prevalence of MetS, whereas the IDF definition
Table 1 Age-adjusted prevalence according to MetS
definition within NHANES cohorts
N ATPIII
2001
ATPIII
revised
WHO IDF
NHANES 1988-1994 [143] 8,814 23.7%
NHANES 1988-1994 [144] 8,608 23.9% 25.1%
NHANES 1988-1994 [145] 6,436 24.1% 29.2%
NHANES 1999-2002 [145] 1,677 27.0% 32.3%
NHANES 1999-2002 [10] 3,601 34.6% 39.1%
NHANES 2003-2006 [13] 3,423 34%
ATPIII = National Cholesterol Education Program Adult Treatment Panel III; IDF
= International Diabetes Federation; MetS = metabolic syndrome; NHANES =
National Health and Examination Survey; WHO = World Health Organization.
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ence, estimated a higher prevalence [14]. Despite the
differing prevalence estimates when employing the var-
ious definitions, they all add up to a shocking figure of a
vast proportion of the population being at high risk of
developing CHD and DMT2.
Both the unadjusted prevalence and age-adjusted pre-
valence of MetS increased from NHANES-III (1988-
1994) to NHANES 1999-2006, from 27.9% to 34.1% and
29% to 34.2%, respectively, but remained the same over
the last NHANES cohorts (1999-2002, and 2003-2006
cohort). In countries from areas other than Europe and
Africa, the IDF guidelines also identify a greater preva-
lence of MetS than the NCEP:ATPIII [15-19]. A similar
prevalence of MetS in the Iranian population was
recently reported, applying both the IDF and ATPIII cri-
teria (32.1% and 33.2% respectively) [20].
In the NHANES 2003-2006 cohort, the prevalence of
MetS was found to increase with age: approximately
20% of males and 16% of females under 40 years of age,
41% of males and 37% of females between 40-59 years,
and 52% of males and 54% of females 60 years and over
[13]. The trend for a higher prevalence of MetS with
advancing age was similar to that observed in other
populations [8,21-25]. This increase with age continues
up to the sixth decade; however, different studies have
estimated a variable prevalence after the sixth or seventh
decades, probably as individuals most susceptible to
obesity-related mortality have already died [22,24,26].
The prevalence of MetS increases even more dramati-
cally as BMI increases. In the NHANES 2003-2006
cohort, overweight males and females were found,
respectively, to be more than 6 and 5.5 times as likely to
meet the criteria for MetS compared to underweight
and normal weight individuals. In obese males and
females compared to underweight and normal weight
individuals these figures spiked to 32 and 17 times,
respectively [13]. Similarly to western societies, the preva-
lence of MetS is rapidly increasing in developing coun-
tries, ranging from 9.8% in male urban North Indians to
42% in female urban Iranians [27]. This increase is
observed regardless of the criteria used and reflects the
transition from a traditional to a Western-like lifestyle.
The emergence of obesity and MetS in developing coun-
tries is related to a number of factors. Demographic tran-
sition (shift to low fertility, low mortality, and higher life
expectancy), and epidemiological transition (from widely
prevalent infectious diseases to a pattern of a high preva-
lence of lifestyle related diseases) evolved in developing
countries as they become economically more resourceful,
leading to significant shifts in dietary and physical activity
patterns. These changes cause significant effects on body
composition and metabolism, often resulting in an
increase in BMI, generalized and abdominal obesity, and
an increase in dyslipidemia and DMT2 [27].
It should be noted however, that even lean individuals
may develop features of MetS adding further to the
complexity of its pathogenesis [28].
Thus, the importance of identifying markers for MetS
to supplement age-related and obesity-related measures
cannot be overstated. Understanding how to use defini-
tion criteria in clinical settings will aid physicians in
treating the right cohort of at-risk patients.
Morbidities related to MetS
The need to precisely define MetS stems from the need to
detect accurately individuals at high risk for CVD and
DMT2. All the components of the various MetS defini-
tions are involved in conferring risk for CVD and DMT2.
In particular, the three components of atherogenic dyslipi-
demia (increased low-density lipoprotein (LDL), decreased
HDL and high blood triglyceride concentrations) are indi-
vidually associated with a cardiovascular risk [29], while IR
significantly increases the risk of developing DMT2,
although approximately 25% of insulin resistant patients
have normal glucose tolerance [30]. Central obesity has
been shown in several studies to be associated with an
increased risk of CVD and DMT2 [31].
Several epidemiological studies have confirmed the
increased risk of CVD in individuals with MetS, inde-
pendently of the diagnostic criteria used [32-39]. Overall
a range of 1.5-3 times greater risk of CVD and CHD
mortality has been found in several prospective studies
(REFS), whereas a recent meta-analysis showed that
MetS was associated with a twofold increase in cardio-
vascular outcomes and a 1.5-fold increase in all-cause
mortality [40]. It should be noted however, that several
studies amongst which the Casale Monferrato Study and
PROSPER conducted in older people, failed to reveal an
association between MetS and an increased risk of CVD
[41,42]. Due to these inconsistencies several recent stu-
dies have aimed to investigate which of the proposed
definitions of MetS is particularly related to excessive
CVD risk, and thus which one should be implemented
in clinical practice. A recent meta-analysis suggested
that the WHO definition was associated with a slightly
greater risk than the NCEP:ATPIII definition [43]. It is
of interest that the INTERHEART study, the first large-
scale multiethnic international investigation, has demon-
strated that using either the WHO or IDF definition,
the presence of MetS is associated with a > 2.5-fold
increase in the risk of acute myocardial infarction (MI)
[44], while Cabre et al. recently reported similar findings
for CVD using these definitions [45].
The assessment of whether the risk of MetS on MI is
greater than the risk conferred by the sum of individual
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report suggested that the MetS-related CVD risk was
more than that of the sum of its parts in subjects with
MetS, with or without DMT2 [46]. In the recent
INTERHEART study, MI risk increased as more compo-
nent factors of MetS were present, and this is consistent
with previous observations showing that the presence of
more risk factors was associated with an incremental
increase in subclinical atherosclerosis and incident CHD
[38,47-49]. One major point of note was that the risk of
CHD when three components of MetS were present did
not appear to be greater than the risk of individual com-
ponents such as DMT2 and hypertension, and this was
in agreement with other reports [50,51]. In this regard,
in a recent appraisal of MetS, the American Diabetes
Association (ADA) in conjunction with the European
Association for the Study of Diabetes, issued a joint
statement raising concerns over the value of using MetS
as a CVD risk marker and recommended that clinicians
should evaluate and treat all CVD risk factors without
considering whether a patient meets the criteria for
diagnosis of MetS [52].
T h eo b s e r v a t i o no ft h ep r e s e n c eo fM e t Sp r e d i c t i n g
the risk for DMT2 has also been examined by numerous
studies; according to these reports, it is well accepted
that the presence of MetS not only increases this risk,
but is also highly predictive of new-onset DMT2
[6,42,53-55]. Indeed, MetS is associated with an approxi-
mately five times higher risk for incident DMT2 [56].
The presence of MetS predicting the incidence of
DMT2 also varies depending on how MetS is defined. It
has previously been demonstrated that definitions like
that of the WHO, which imposes as a prerequisite the
presence of impaired fastingg l u c o s e( I F G )a n d / o rI G T ,
confer a higher risk than the NCEP:ATPIII and IDF
definitions, which consider elevated fasting plasma glu-
cose as an essential, but not required component [57].
IFG and IGT can predict the development of DMT2,
independently of other components of MetS [56]. How-
ever, recent studies have shown that the IDF and NCEP:
ATPIII definitions of MetS predicted DMT2 at least as
well as the WHO definition [58,59].
Although the presence of MetS can predict the CVD
and DMT2 risk, it cannot estimate the exact risk, as a
significant part may be related to other factors such as
age, smoking or gender. In particular, women have
higher concentrations of inflammatory markers, such as
high sensitivity C reactive protein (hs-CRP), compared
to men, attributed possibly to their increased accumula-
tion of subcutaneous and/or visceral fat [60,61]. Addi-
tionally, factors others than those included in the
existing definitions of MetS, such as endothelial dys-
function, small dense oxidized LDL, insulin resistance,
prothrombotic tendency and a proinflammatory state
that are essential components and determinant of future
cardiometabolic risk have been left out. Indeed, a substan-
tial amount of knowledge on cardiometabolic risk is pro-
vided by markers that define a proinflammatory state,
such as hs-CRP, g-glutamyltransferase (g-GT), uric acid,
apoB, apoE, fibrinogen, along with the associated dysfunc-
tion of apolipoprotein A-I (ApoA-I) and HDL [62-67]. In
particular, HDL dysfunctionality is closely linked to obesity
and low-grade inflammation yet seems to act partly inde-
pendently of them. Although it is not as yet clear what is
the exact contribution of these risk factors to the develop-
ment of CVD and DMT2, it is probable that along with
the mechanisms delineated further below, may account for
the residual risk not attributed to the traditional risk fac-
tors of these disorders.
Conditions contributing to the pathogenesis of MetS
(Figure 1)
Despite advances in pathophysiology and delineation of
risk factors that predispose to MetS, there are many key
aspects that remain unclear. The great variation in sus-
ceptibility and age of onset in individuals with a very
similar risk profile, suggests a major interaction between
genetic and environmental factors [68]. Although obesity
and IR remain at the core of the pathophysiology of
MetS, a number of other factors such as chronic stress
and dysregulation of the hypothalamic-pituitary-adrenal
(HPA) axis and autonomic nervous system (ANS),
increases in cellular oxidative stress, renin-angiotensin-
aldosterone system activity, and intrinsic tissue gluco-
corticoid actions, as well as currently discovered mole-
cules such as micro RNAs can also be involved in its
pathogenesis (Figure 1).
Conditions epidemiologically confirmed
Obesity/insulin resistance and MetS Although not all
overweight or obese individuals are metabolically dis-
turbed, the majority are IR [69-71]. Central obesity is
thought to be an early step, as visceral adipose tissue
secretes a variety of bioactive substances termed adipo-
cytokines, such as leptin, resistin, tumor necrosis factor
a (TNFa), interleukin-6 (IL-6), and angiotensin II which
induce IR, along with plasminogen activator inhibitor 1
(PAI-1), which is related to thrombogenic vascular dis-
eases [72]. Notably, adiponectin, an important adipocy-
tokine that protects against the development of DMT2,
hypertension, inflammation, and atherosclerotic vascular
diseases, is decreased in individuals with visceral fat
accumulation, and this may be causally related to MetS
[73,74]. Moreover, newly recognized adipocytokines
such as visfatin, as well as enzymes expressed in adipose
tissue, such as neprilysin, and growth factors, like fibro-
blast growth factor 21, an important regulator of glucose
and lipid metabolism, are currently under investigation
regarding their role in the pathogenesis of MetS [75-77].
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lin-mimicking/sensitizing effects but can also contribute
to the inflammatory processes by triggering cytokine
production and nuclear factor B( N F - B) activation,
while vice versa visfatin secretion is upregulated in
response to proinflammatory cytokines [78].
Other compounds produced by adipose tissue possibly
implicated in the pathogenesis of MetS, are the non-
esterified free fatty acids (FFAs). In the presence of IR
the process of FFAs mobilization from stored adipose
tissue triglycerides is accelerated. In the liver, FFAs
result (due to hepatic insulin resistance) in increased
production of glucose and triglycerides and secretion of
very low-density lipoprotein (VLDL), maintaining a
vicious cycle. FFAs also reduce insulin sensitivity in
muscle by inhibiting insulin-mediated glucose uptake
and increase fibrinogen and PAI-1 production [9,79].
Conditions related to MetS without epidemiological
confirmation
Chronic stress: dysregulation of HPA axis/ANS and
MetS Chronic hypersecretion of stress mediators, such
as cortisol, in individuals with a genetic predisposition
exposed to a permissive environment, may lead to visc-
eral fat accumulation as a result of chronic hypercortiso-
lism, low growth hormone secretion and hypogonadism
[80,81]. Moreover, hypercortisolism directly causes IR of
peripheral target tissues in proportion to glucocorticoid
(GC) levels and a particular target tissue’s sensitivity to
them as shown by studying polymorphisms of the gluco-
corticoid receptor gene [82]. These hormonal alterations
may lead to reactive insulin hypersecretion, and increas-
ing visceral obesity and sarcopenia, resulting to dyslipi-
demia, hypertension and DMT2 [83]. Stress-related IL-6
hypersecretion plus adipose-tissue-generated inflamma-
tory hypercytokinemia, as well as hypercortisolism, con-
tribute to increased production of acute phase reactants
and blood hypercoagulation, which have been recently
recognized as components of MetS [84,85].
Moreover, since intracellular GC levels are regulated
by 11b-hydroxysteroid dehydrogenase type 1 (11b-
HSD1), which converts inactive cortisone to cortisol, a
large number of studies have focused on evaluating
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Figure 1 A schematic image of the conditions implicated in the pathophysiology of the metabolic syndrome and their potential
interactions. IR: Insulin Resistance; HTN: Hypertension; HPA axis : Hypothalamic-Pituitary-Adrenal Axis; DMT2: Diabetes Mellitus type 2; CVD:
Cardiovascular disease; CRH: Corticotropin Releasing Hormone; AVP: Arginine Vasopressin.
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activity in obesity and IR. In obesity global 11b-HSD1
activity, as measured by urinary corticosteroid metabo-
lite analysis, is impaired [86,87], while selective 11b-
HSD1 inhibitors, are in development with promising
results showing improvements in metabolic profile in
rodents [88].
A possible association between visceral fat/insulin
resistance, inflammatory cytokines, stress hormones, and
sleep apnea has recently been suggested [89-91]. Visc-
eral obesity/insulin resistance, determined by both
genetic/constitutional and environmental factors, may
be the principal culprit leading to sleep apnea, which, in
turn, may accelerate these metabolic abnormalities, pos-
sibly through progressive elevation of stress hormones
and cytokines such as noradrenaline, cortisol, IL-6, and
TNFa [92].
Apart from the stress HPA axis and its end effectors
glucocorticoids, another system, the circadian CLOCK
system may also be implicated in the pathogenesis of
MetS. Interestingly, most of the metabolic phenotypes
associated with dysregulation of the CLOCK system and
the HPA axis overlap [93].
Cellular oxidative stress/renin-angiotensin-aldoster-
one system and MetS Emerging evidence suggests that
nitric oxide (NO), inflammatory and oxidative stress
also play important roles in the pathophysiology of
MetS hypertension and DMT2 [94,95]. Increased pro-
duction of reactive oxygen species (ROS) in numerous
tissues, including skeletal muscle and cardiovascular tis-
sues, has been linked (amongst others) to activation of
the renin-angiotensin-aldosterone system [96,97], which
is also implicated in the development of IR [98]. Eleva-
tion of angiotensin II can induce IR via reactive oxygen
species (ROS) production in various tissues, including
vascular smooth muscle and skeletal muscle in patients
with MetS [96,98]. Furthermore, either use of angioten-
sin II type 1 receptor antagonists or genetic knockout of
angiotensin II type 1 receptor are known to effectively
attenuate lipid accumulation in the liver [99-105].
Micro RNAs and MetS Micro RNAs (miRNAs) play
important regulatory roles in a variety of biological pro-
cesses including adipocyte differentiation, metabolic
integration, IR and appetite regulation [106]. Although
the exact mechanism of action remains to be elucidated,
miRNAs may regulate cellular gene expression at the
transcriptional or post-transcriptional level, by suppres-
sing translation of protein-coding genes, or cleaving tar-
get messenger RNAs (mRNAs) to induce their
degradation, through imperfect pairing with target
mRNAs [107,108]. Antagomirs (cholesterol conjugated
antisense oligonucleotides) which target and silence
miRNAs, as evidenced by hepatic miR-122 blockade in
vivo [109], have already been successfully tested in a
phase I clinical trial. Further studies are needed to
explore the full potential of miRNAs as novel biomar-
kers and therapeutic agents against MetS.
Fetal/developmental basis of MetS The concept of
fetal/developmental origin of MetS, since the first study
linking intrauterine undernutrition with later obesity,
continues to raise interest [110]. Evidence from both
human [111,112] and animal studies [113,114] suggests
that the nutritional, hormonal, and metabolic environ-
ment of the mother, as well as the early postnatal envir-
onment, may permanently reprogram the structure and
physiology of the offspring toward the development of
metabolic disease, in later life [80,84,115,116].
Since in vitro fertilization (IVF) has been widely used,
the possible effect of IVF (as a result of either intrauter-
ine growth restriction or periconceptual manipulation of
the blastocysts per se) in the incidence of MetS manifes-
tations has been studied, producing conflicting results
[117-119]. More prospective studies on the metabolic
profile of children conceived by IVF, with longer follow-
up are necessary to draw safe conclusions.
Although the role of the all these components as inte-
gral parts of MetS has not been evaluated in epidemio-
logical and interventional studies, they may represent
the missing link that provides full susceptibility to CVD
besides the traditionally accepted components of MetS.
This is particularly relevant for the fetal programming
as it may suggest intervention at an earlier stage with
lifestyle therapies, since the incidence of MetS in chil-
dren and adolescents is increasing alarmingly.
Is the pediatric metabolic syndrome real or a myth? A
developmental perspective
The increasing worldwide prevalence of childhood obesity
and, in parallel, of DMT2 in the young [120,121], has high-
lighted the importance of MetS diagnosis in children and
adolescents, as a state of high risk for progression to later
disease. Since the first publication of MetS in children, in
1999, [122], a growing interest emerged investigating MetS
prevalence and the potential utility of this diagnosis, as
well as therapeutic interventions in adolescents fulfilling it.
Later, findings from the Third National Health and Nutri-
tion Examination Survey (NHANES), 1988-1994 [123]
revealed that 4.2% of adolescents in general, and almost
30% of overweight and obese adolescents, in the US met
diagnostic criteria for MetS. A variety of subsequent stu-
dies [120,123-131], using three or four criteria and variable
definitions, revealed diversity in MetS prevalence in child-
hood. The NHANES 1999-2000, using the ATPIII defini-
tion modified for age, identified a further increase in
the prevalence of MetS among US adolescents, from
4.2% in NHANES III (1988-1994) to 6.4% in NHANES
(1999-2000) [127]. The prevalence of MetS was almost
exclusively found to be high among obese adolescents.
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Similarly to adults, no general consensus exists regard-
ing the definition of MetS in children and adolescents
[132]. Furthermore, studies published so far have used
their own set of variables, number of criteria (three or
four) and different cut-off points to define risk factors
associated with MetS. Obesity has been defined as the
85th to 97th percentile of BMI or waist circumference,
while accordingly, a variety of cut-off percentiles have
been used for blood pressure, triglycerides, HDL, insulin
and glucose [133]. In 2007, a consensus report was pub-
lished by the IDF group [134], including three age
groups: 6 to < 10, 10 to < 16 and 16 + years (adult cri-
teria). Based on this report, obesity is defined as waist
circumference ≥ 90th percentile, or adult cut-off if
lower, while all other parameters are defined based
on absolute numbers, rather than percentiles. These
numbers are: ≥ 150 mg/dl for triglycerides (or specific
treatment for triglycerides), < 40 mg/dl for HDL and
< 50 mg/dl in females older than 10 (or specific treatment
for HDL), ≥ 130 mmHg for systolic and ≥ 85 mmHg
for diastolic blood pressure (or treatment of previously
diagnosed hypertension) and fasting plasma glucose
≥ 100 mg/dl or known type 2 diabetes. The rationale of
using absolute numbers as cut-offs is based on the hetero-
geneity of clinical, biochemical and hormonal values dur-
ing childhood and adolescence, as well as, on the large
diversity of proposed percentile cut-offs of different defini-
tions. The IDF definition is presented in detail in Table 2.
The pediatric perspective: challenges in conceptual models
The main concern for pediatric clinicians is that all
childhood MetS definitions originate from adult defini-
tions and use criteria extrapolated from an adult diagno-
sis to a younger age group, while, in fact, the utility and
predictive value of this diagnosis in young age groups
has not been fully established. Indeed, large longitudinal
studies linking pediatric MetS with adult cardiovascular
disease are limited, and although it is hypothesized that
MetS in childhood is related to MetS in adulthood, this
hypothesis has not yet been tested. A second important
issue is the lack of a developmental perspective in MetS
definition: MetS as an entity is developing progressively,
according to age and pubertal changes, so that the full
MetS cannot in general be easily diagnosed in childhood
[124]. Developmentally-appropriate risk or protective
factors, such as gestational age, birth weight and breast-
feeding, as well as parental obesity and family history,
are not typically taken into account [133]. More impor-
tantly, none of the MetS definitions consider the influ-
ences of growth and puberty, for instance the ‘normal’
insulin resistance in puberty [135,136], the changes in
fat and fat-free mass and the changes in growth and
sex steroid secretion. Further to these changes, it has
been shown that in obese children, insulin resistance
(as measured by the homeostasis model assessment-
insulin resistance (HOMA-IR) index) increases progres-
sively across Tanner stages and is higher in all pubertal
stages than in normal weight children [137].
MetS consistency in adolescence
Recently published studies examined MetS stability in
large epidemiological samples of adolescents, using fac-
tor analysis. It was found that, though metabolic risk
factor clustering was consistent, the categorical diagno-
sis of MetS was not stable during adolescence [138],
including both gain and loss of diagnosis. A second,
more recent study from the same group, examined the
stability of three alternative models of MetS factor struc-
ture across three developmental changes [139]. The
researchers suggested that the concepts used to support
the utility of MetS in the young do not fit to pediatric
populations and may vary by maturation. In addition to
these large epidemiological studies, from US, clinical
data also support this idea. Our research group exam-
ined the prevalence and stability of MetS diagnosis in
children and adolescents aged 8-16. Data from our
cohort showed that in a clinical population of obese
children followed at our obesity outpatient clinic, almost
10% had the full MetS, and another 30% had partial
MetS (two positive parameters of MetS). When examin-
ing the effects of puberty, we found that pubertal chil-
dren had a higher prevalence of full and partial MetS
than the prepubertal population. However, this diagnosis
presented a within-person variability when examined at
different time points during adolescence [140]. This new
information is further supported by recently published
data from the Bogalusa Heart Study and the Cardiovas-
cular Risk in Young Finns [141]. This study has shown
that although children and adolescents with MetS are
indeed at an increased risk of adult MetS, subclinical
atherosclerosis and diabetes type 2, the BMI alone is an
equally accurate measure as MetS in identifying youth
at risk for adult MetS and subsequent atherosclerotic
disease.
Clinical implications for pediatric MetS
MetS as a concept was originally developed to identify
adults at a greatest risk for CVD and DMT2, however,
the application of this model has not yet been fully vali-
dated in children and adolescents. Furthermore, the
effects of growth and puberty on reference values is a cri-
tical issue, because diverse age-dependent cut-off points
are needed to define a pathological state, such as MetS.
Longitudinally, the high level of diagnostic inconsistency
through adolescence suggests that MetS classification
may not be a valuable method for risk identification in
the pediatric age group.
These limitations, as well as new data from longitudi-
nal studies in pediatric MetS, suggest that prevention
and treatment in childhood and adolescence should
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diagnosis of MetS. Pediatric clinicians may put more
emphasis on healthy lifestyle promotion and obesity pre-
vention and treatment rather than targeting specific meta-
bolic alterations. Indeed, advocating weight maintenance
rather than weight loss during the years of physical growth,
may lead to BMI reduction and cardiovascular risk mini-
mization and may be a more cost-effective approach than
pursuing fluctuating biochemical abnormalities.
Conclusions
Due to its impact upon health and financial implica-
tions, the mechanisms that contribute to the pathogen-
esis of MetS remain under intense investigation since
their understanding may help design novel therapeutic
strategies. A number of potential mechanisms contribut-
ing to the pathogenesis of MetS include fetal program-
ming, dyshomeostasis of the stress system, and the
development of a proinflammatory and prothrombotic
state as a result of cytokine production and/or dysregu-
lation from the excessive adipose tissue. Delineation of
the role of these factors along with the established ones
and others that are currently being studied may help
clarify the exact pathogenesis of the syndrome and may
expand the clinical criteria of MetS. This is particularly
important as there is still a need to develop uniform cri-
teria that can be used by different clinical and research
groups, enabling comparisons between study results, in
the hope to better predictor the risk, for CVD and
DMT2. In this direction, further studies exploring the
relation of waist circumference thresholds to metabolic
risk and cardiovascular outcomes in different populations
are encouraged. However, until this aim is achieved, the
consensus definition incorporating IDF and AHA/
NHLBI is, in our opinion, the most suitable for practical
use in clinical medicine. Adoption of these criteria seem
to incorporate the most important aspects of the syn-
drome, recognizing that the risk associated with a parti-
cular waist measurement will differ in different
populations, albeit with the limitations that it has when
applied to mixed ethnicities. Finally, the application of
the MetS model has not been fully validated in children
and adolescents as yet, suggesting that prevention and
treatment in childhood and adolescence should better
focus on established risk factors rather than the diagno-
sis of MetS.
Appendix 1
Criteria for metabolic syndrome (MetS) definitions in
adults
World Health Organization criteria (1998) [2]
Insulin resistance is defined as type 2 diabetes mellitus
(DM) or impaired fasting glucose (IFG) (> 100 mg/dl)
or impaired glucose tolerance (IGT), plus two of the fol-
lowing:
￿ Abdominal obesity (waist-to-hip ratio > 0.9 in men
or > 0.85 in women, or body mass index (BMI) > 30
kg/m
2.
￿ Triglycerides 150 mg/dl or greater, and/or high-
density lipoprotein (HDL)-cholesterol < 40 mg/dl in
men and < 50 mg/dl in women.
￿ Blood pressure (BP) 140/90 mmHg or greater.
￿ Microalbuminuria (urinary albumin secretion rate
20 μg/min or greater, or albumin-to-creatinine ratio
30 mg/g or greater).
Table 2 International Diabetes Federation (IDF) definition for pediatric metabolic syndrome (MetS) [134]
Age
group
(years)
Obesity (WC) Triglycerides HDL-C Blood pressure Glucose
6t o<
10
a
≥ 90th percentile
10 to
<1 6
≥ 90th percentile or adult cut-off
if lower
≥ 1.7 mmol/l (≥ 150
mg/dl)
< 1.03 mmol/l (< 40 mg/dl) Systolic BP ≥ 130 or diastolic
BP ≥ 85 mm Hg
FPG ≥ 5.6
mmol/l (100
mg/dl)
b or
known T2DM
16+
(adult
criteria)
WC ≥ 94 cm for Europid males
and ≥ 80 cm for Europid
females, with ethnic-specific
values for other groups
c
≥ 1.7 mmol/l (≥ 150
mg/dl) or specific
treatment for high
triglycerides
< 1.03 mmol/l (< 40 mg/dl) in
males and < 1.29 mmol/l (<
50mg/dl) in females, or specific
treatment for low HDL
Systolic BP ≥ 130 or diastolic
BP ≥ 85 mm Hg or
treatment of previously
diagnosed hypertension
FPG ≥ 5.6
mmol/l (100
mg/dl)
b or
known T2DM
Diagnosing metabolic syndrome requires the presence of central obesity plus any two of the other four factors.
aMetabolic syndrome cannot be diagnosed, but further measurements should be made if there is a family history of metabolic syndrome, T2DM, dyslipidemia,
cardiovascular disease, hypertension and/or obesity.
bFor clinical purposes, but not for diagnosing MetS, if FPG: 5.6-6.9 mmol/l (100-125 mg/dl) and not known to have diabetes, an oral glucose tolerance test should
be performed.
cFor those of South and South-East Asian, Japanese, and ethnic South and Central American origin, the cut-offs should be ≥ 90 cm for men, and ≥ 80 cm for
women. The IDF Consensus group recognizes that there are ethnic, gender and age differences, but research is still needed on outcomes to establish risk.
BP = blood pressure; FPG = fasting plasma glucose; HDL-C = high-density lipoprotein cholesterol; IDF = International Diabetes Federation; T2DM = type2
diabetes mellitus; WC = waist circumference.
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criteria (1999) [3]
Insulin resistance defined as insulin levels > 75th percen-
tile of non-diabetic patients, plus two of the following:
￿ Waist circumference 94 cm or greater in men, 80
cm or greater in women.
￿ Triglycerides 150 mg/dl or greater and/or HDL-
cholesterol < 39 mg/dl in men or women.
￿ BP 140/90 mmHg or greater or taking antihyper-
tensive drugs.
￿ Fasting glucose 110 mg/dl or greater.
National Cholesterol Education Program Adult Treatment
Panel III (NCEP:ATPIII) criteria (2001) [4]
Any three or more of the following:
￿ Waist circumference > 102 cm in men, > 88 cm in
women.
￿ Triglycerides 150 mg/dl or greater.
￿ HDL-cholesterol < 40 mg/dl in men and < 50 mg/
dl in women.
￿ BP 130/85 mmHg or greater.
￿ Fasting glucose 110 mg/dl* or greater.
* In 2003, the American Diabetes Association (ADA)
changed the criteria for IFG tolerance from 110 mg/dl
to 100 mg/dl.
American Association of Clinical Endocrinology criteria
(2003) [142]
IGT plus two or more of the following:
￿ BMI 25 kg/m
2 or greater.
￿ Triglycerides 150 mg/dl or greater and/or HDL-
cholesterol < 40 mg/dl in men and < 50 mg/dl in
women.
￿ BP 130/85 mmHg or greater.
International Diabetes Federation (IDF) criteria (2005) [5]
Central obesity (defined as waist circumference but can
b ea s s u m e di fB M I>3 0k g / m
2) with ethnicity-specific
values,* plus two of the following:
￿ Triglycerides 150 mg/dl or greater.
￿ HDL-cholesterol < 40 mg/dl in men and < 50 mg/
dl in women.
￿ BP 130/85 mmHg or greater.
￿ Fasting glucose 100 mg/dl or greater.
*To meet the criteria, waist circumference must be:
for Europeans, > 94 cm in men and > 80 cm in women;
and for South Asians, Chinese, and Japanese, > 90 cm
i nm e na n d>8 0c mi nw o m e n .F o re t h n i cS o u t ha n d
Central Americans, South Asian data are used, and for
sub-Saharan Africans and Eastern Mediterranean and
Middle East (Arab) populations, European data are
used.
American Heart Association/National Heart, Lung, and
Blood Institute (AHA/NHLBI) criteria (2004) [6]
Any three of the following:
￿ Waist circumference 102 cm or greater in men, 88
cm or greater in women.
￿ Triglycerides 150 mg/dl or greater.
￿ HDL-cholesterol < 40 mg/dl in men and < 50 mg/
dl in women.
￿ BP 130/85 mmHg or greater.
￿ Fasting glucose 100 mg/dl or greater.
Consensus definition (incorporating IDF and AHA/NHLBI
definitions) [7]
Any three of the following:
￿ Elevated waist circumference (according to popula-
tion and country-specific definitions).
￿ Triglycerides 150 mg/dl or greater.
￿ HDL-cholesterol < 40 mg/dl in men and < 50 mg/
dl in women.
￿ BP 130/85 mmHg or greater.
￿ Fasting glucose 100 mg/dl or greater.
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